Penn analysis shows low risk of secondary cancers following CAR T cell therapy

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.

Related Keywords

David Porter ,Jodi Fisher Horowitz ,Marco Ruella ,Lymphoma Program ,Abramson Cancer Center ,University Of Pennsylvania ,University Of Pennsylvania School Medicine ,Perelman School Of Medicine ,Pennsylvania School ,Penn Medicine ,Perelman School ,Scientific Director ,Penn Medicine Cellular Therapy ,Transplant Biobank ,Leukemia Care Excellence ,Cell Therapy ,Abramson Cancer ,Cell ,Medicine ,Flood ,Dancer ,Cancer Treatment ,Chemotherapy ,Gene ,Hospital ,Immunotherapy ,Lymph Node ,Lymphoma ,Research ,T Cell ,Transplant ,Humor ,